The American College of Rheumatology (ACR), which represents over 9500 rheumatologists and rheumatology health professionals, recently submitted a letter to HHS in response to the department’s request for information on Promoting Healthcare Choice and Competition Across the United States.
The American College of Rheumatology (ACR), which represents over 9500 rheumatologists and rheumatology health professionals, recently submitted a letter to HHS in response to the department’s request for information on Promoting Healthcare Choice and Competition Across the United States.
In the letter, the ACR applauded CMS’ recent decision to assign unique J-codes to each biosimilar of a reference product and encouraged HHS to continue to support biosimilar innovation. Allowing biosimilars to have their own unique J-code ensures better monitoring of their effectiveness while allowing for sufficient pharmacovigilance.
ACR urged Congressional leaders to reverse a recent decision to adjust providers’ reimbursement for Part B drug costs based on their performance under the Merit-Based Incentive Payment System (MIPS), despite these drugs’ costs being outside physician control. ACR claims that both reforms are essential to advancing the current administration’s goals of promoting healthcare choice and competition.
“This dangerous policy penalizes the doctors who administer Part B therapies and will ultimately reduce patient access to treatments for diseases like arthritis and cancer, particularly in rural and underserved areas of the United States. This is in direct conflict with the Administration’s goal of promoting patient choice,” said David Daikh, MD, PhD, president of ACR, in a statement.
ACR also called on HHS to address the problem of prior authorizations. The letter cites a 2016 American Medical Association (AMA) survey that found that medical practices on average complete 37 prior authorization requirements per week, per physician. This process takes about 16 hours (or 2 full business days). ACR says that CMS (and other entities that are engaged in reform) should follow a group of principles outlined in the letter:
“The current prior authorization process leads to a waste of valuable resources that delays care and does not add value to the healthcare delivery system. We encourage HHS and all agencies involved in utilization management to follow a set of best practices that ensure utilization management programs are reasonably designed and implemented,” said Daikh.
Another area of concern for ACR is the need for increased transparency from pharmacy benefit managers (PBMs). The ACR suggested that CMS consider policies that provide more transparency about PBMs payment practices, including the true cost of drugs. ACR also encouraged HHS to require more consistency in the way PBMs structure their rebate programs, including uniform definitions for terms used in disclosures, such as specifying what constitutes a rebate, discount, fee, and amount received from a manufacturer.
Along with ACR, more than 100 healthcare organizations sent letters to congressional leaders urging them to reverse the CMS policy, cautioning that it will create a tremendous financial risk for specialists that administer Part B drugs and lead to significant access problems for patients that rely on these therapies.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.
2 Commerce Drive
Cranbury, NJ 08512